Vitamin Shoppe, Inc (NYSE:VSI) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Vitamin Shoppe is a specialty retailer and direct marketer of nutritional products. It primarily sells vitamins, minerals, nutritional supplements, herbs, sports nutrition formulas, homeopathic remedies, green living products and health and beauty aids. Based in North Bergen, New Jersey, the company is recognized as an innovator in providing product information, associate training, and customer education. Information is available to consumers through unprecedented outlets including television, radio, friends, family, health practitioners, and the internet. It offers consumers the opportunity to take charge of their own health and wellness requirements, and supplement where necessary. At each store location, consumers can find a comprehensive Learning Center which offers free access to vital information about key health concerns and products. The Vitamin Shoppe is a strong supporter of health and wellness campaigns including Life Supplemented sponsored by the Council for Responsible Nutrition. “

Several other equities analysts have also issued reports on the stock. ValuEngine lowered shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Barclays PLC reissued an “equal weight” rating and set a $13.00 price objective (down from $24.00) on shares of Vitamin Shoppe in a report on Sunday, May 14th. Gabelli lowered shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Morgan Stanley raised shares of Vitamin Shoppe from an “underweight” rating to an “equal weight” rating and set a $14.00 price objective on the stock in a report on Thursday, May 11th. Finally, Goldman Sachs Group, Inc. (The) cut their price objective on shares of Vitamin Shoppe from $22.00 to $19.00 and set a “sell” rating on the stock in a report on Thursday, March 23rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $24.00.

Vitamin Shoppe (NYSE:VSI) opened at 10.95 on Tuesday. Vitamin Shoppe has a 12-month low of $9.80 and a 12-month high of $32.31. The stock has a market cap of $253.63 million, a P/E ratio of 14.09 and a beta of 0.69. The firm’s 50 day moving average price is $11.54 and its 200-day moving average price is $18.74.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings results on Wednesday, May 10th. The specialty retailer reported $0.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by $0.21. Vitamin Shoppe had a net margin of 1.43% and a return on equity of 9.35%. The company had revenue of $316.90 million for the quarter, compared to the consensus estimate of $325.71 million. During the same period in the prior year, the firm posted $0.67 EPS. The business’s revenue was down 5.9% on a year-over-year basis. Equities research analysts anticipate that Vitamin Shoppe will post $1.57 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Vitamin Shoppe, Inc (VSI) Upgraded by Zacks Investment Research to “Hold”” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/18/vitamin-shoppe-inc-vsi-upgraded-by-zacks-investment-research-to-hold.html.

Institutional investors have recently modified their holdings of the stock. Financial & Investment Management Group Ltd. raised its position in Vitamin Shoppe by 73.2% in the second quarter. Financial & Investment Management Group Ltd. now owns 144,654 shares of the specialty retailer’s stock valued at $1,685,000 after buying an additional 61,155 shares in the last quarter. Capstone Asset Management Co. raised its position in Vitamin Shoppe by 3.5% in the second quarter. Capstone Asset Management Co. now owns 14,040 shares of the specialty retailer’s stock valued at $164,000 after buying an additional 470 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Vitamin Shoppe during the first quarter valued at about $11,515,000. Credit Suisse AG raised its position in Vitamin Shoppe by 1.2% in the first quarter. Credit Suisse AG now owns 72,256 shares of the specialty retailer’s stock valued at $1,456,000 after buying an additional 863 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its position in Vitamin Shoppe by 122.7% in the first quarter. Tudor Investment Corp ET AL now owns 28,500 shares of the specialty retailer’s stock valued at $574,000 after buying an additional 15,700 shares in the last quarter.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.